BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 31362708)

  • 1. Exceptional response to chemotherapy followed by concurrent radiotherapy and immunotherapy in a male with primary retroperitoneal serous Adenocarcinoma: a case report and literature review.
    Chae YK; Saleem N; Roh Y; Bilal H; Viveiros P; Sukhadia B; Lin X; Sheikh MM; Park LC
    BMC Cancer; 2019 Jul; 19(1):748. PubMed ID: 31362708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case of primary retroperitoneal serous adenocarcinoma.
    Arichi N; Yasumoto H; Mitsui Y; Hiraoka T; Honda S; Shiina H; Igawa M
    Int J Urol; 2011 Dec; 18(12):844-6. PubMed ID: 21992013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
    Afzal MZ; Mabaera R; Shirai K
    J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nivolumab and its use in the second-line treatment of metastatic urothelial cancer.
    Raggi D; Necchi A; Giannatempo P
    Future Oncol; 2018 Nov; 14(26):2683-2690. PubMed ID: 29927336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A primary retroperitoneal serous cystadenocarcinoma with clinically aggressive behavior.
    Kaku M; Ohara N; Seima Y; Imanishi K; Tomura N; Kobayashi A; Yamasaki M; Hirata Y; Murao S
    Arch Gynecol Obstet; 2004 Dec; 270(4):302-6. PubMed ID: 14551796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resection for Primary Retroperitoneal Serous Adenocarcinoma and Liver Metastasis.
    Nakatake R; Ishizaki M; Ishida M; Matsui K; Kawaguchi Y; Kaibori M
    Intern Med; 2018 Dec; 57(23):3371-3375. PubMed ID: 30101904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-PD-1 immunotherapy in combination with sequential involved-site radiotherapy in heavily pretreated refractory Hodgkin lymphoma.
    Quéro L; Gilardin L; Fumagalli I; Martin V; Guillerm S; Bauduceau O; Kirova YM; Hennequin C; Brice P
    Cancer Radiother; 2019 Apr; 23(2):132-137. PubMed ID: 30733172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Added value of contrast-enhanced ultrasound (CEUS) in the diagnosis of primary retroperitoneal serous adenocarcinoma: a case report.
    Zhou LY; Zhu XD; Jiang J; Bai YF; Jiang TA
    BMC Med Imaging; 2021 May; 21(1):80. PubMed ID: 33980163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary malignant melanoma of the esophagus, treated with immunotherapy: a case report.
    Rochefort P; Roussel J; de la Fouchardière A; Sarabi M; Desseigne F; Guibert P; Cattey-Javouhey A; Mastier C; Neidhardt-Berard EM; de la Fouchardière C
    Immunotherapy; 2018 Aug; 10(10):831-835. PubMed ID: 30073896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer.
    Mehrvarz Sarshekeh A; Overman MJ; Kopetz S
    Future Oncol; 2018 Aug; 14(18):1869-1874. PubMed ID: 29473436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Chemotherapy Following Anti-PD-1 Antibody Therapy for Gastric Cancer: A Case of Sclerosing Cholangitis.
    Kono M; Sakurai T; Okamoto K; Masaki S; Nagai T; Komeda Y; Kamata K; Minaga K; Yamao K; Takenaka M; Watanabe T; Nishida N; Kudo M
    Intern Med; 2019 May; 58(9):1263-1266. PubMed ID: 30626829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A man with recurrent hypovolemic shock on anti-programmed cell death protein 1 treatment: Immune-related protein-losing enteropathy.
    Lee SY; Kim MH; Jang M; Park Y; Cho BC
    Eur J Cancer; 2018 Nov; 104():104-107. PubMed ID: 30342309
    [No Abstract]   [Full Text] [Related]  

  • 13. There and back again: An immunotherapy tale.
    Guo Y; Krupnick AS
    J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1771-1774. PubMed ID: 29409610
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients.
    Osa A; Uenami T; Koyama S; Fujimoto K; Okuzaki D; Takimoto T; Hirata H; Yano Y; Yokota S; Kinehara Y; Naito Y; Otsuka T; Kanazu M; Kuroyama M; Hamaguchi M; Koba T; Futami Y; Ishijima M; Suga Y; Akazawa Y; Machiyama H; Iwahori K; Takamatsu H; Nagatomo I; Takeda Y; Kida H; Akbay EA; Hammerman PS; Wong KK; Dranoff G; Mori M; Kijima T; Kumanogoh A
    JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term control and partial remission after initial pseudoprogression of glioblastoma by anti-PD-1 treatment with nivolumab.
    Roth P; Valavanis A; Weller M
    Neuro Oncol; 2017 Mar; 19(3):454-456. PubMed ID: 28039369
    [No Abstract]   [Full Text] [Related]  

  • 16. Adjuvant Pelvic Radiation "Sandwiched" Between Paclitaxel/Carboplatin Chemotherapy in Women With Completely Resected Uterine Serous Carcinoma: Long-term Follow-up of a Prospective Phase 2 Trial.
    Frimer M; Miller EM; Shankar V; Girda E; Mehta K; Smith HO; Kuo DYS; Goldberg GL; Einstein MH
    Int J Gynecol Cancer; 2018 Nov; 28(9):1781-1788. PubMed ID: 30371562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy With Programmed Cell Death 1 Inhibitors for 5 Patients With Conjunctival Melanoma.
    Sagiv O; Thakar SD; Kandl TJ; Ford J; Sniegowski MC; Hwu WJ; Esmaeli B
    JAMA Ophthalmol; 2018 Nov; 136(11):1236-1241. PubMed ID: 30352118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to PD1 inhibition in conventional chondrosarcoma.
    Wagner MJ; Ricciotti RW; Mantilla J; Loggers ET; Pollack SM; Cranmer LD
    J Immunother Cancer; 2018 Sep; 6(1):94. PubMed ID: 30253794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Squamous Cell Carcinomas of the Head and Neck Cancer Response to Programmed Cell Death Protein-1 Targeting and Differential Expression of Immunological Markers: A Case Report.
    Merhi M; Raza A; Inchakalody VP; Nashwan AJJ; Allahverdi N; Krishnankutty R; Uddin S; Zar Gul AR; Al Homsi MU; Dermime S
    Front Immunol; 2018; 9():1769. PubMed ID: 30108590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy.
    Finazzi T; Rordorf T; Ikenberg K; Huber GF; Guckenberger M; Garcia Schueler HI
    BMC Cancer; 2018 Apr; 18(1):395. PubMed ID: 29625593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.